<DOC>
	<DOC>NCT00098241</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.</brief_summary>
	<brief_title>Safety &amp; Efficacy of Certican in Pediatric de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male and female patients no more than 16 years of age. Patients receiving a primary cadaveric or nonHLA identical living donor (related or unrelated) renal transplant. The graft must be functional within 48 hours post transplantation. Cold ischemia time greater than 40 hours. Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs. Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pediatric</keyword>
	<keyword>renal</keyword>
	<keyword>transplant recipients</keyword>
	<keyword>de novo</keyword>
	<keyword>De novo renal pediatric transplant</keyword>
</DOC>